Cyramza ® (ramucirumab) injection

10 mg/mL solution

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

CYRAMZA® (ramucirumab): Administration

Administer Cyramza (ramucirumab) as an IV infusion in a separate line. Use of a protein-sparing 0.22-micron filter is recommended.

Calculate and Prepare Ramucirumab for Administration

Visually inspect vials for particulate matter and discoloration. Discard if particulate matter or discolorations are identified.1

Calculate the dose and the required volume of ramucirumab needed for the calculated dose. Withdraw the required volume of ramucirumab and further dilute with only 0.9% sodium chloride injection in an IV infusion container to a final volume of 250 mL. Do not use dextrose-containing solutions.1

Gently invert the container to ensure adequate mixing. Do not shake the infusion solution. Do not dilute with other solutions or co-infuse with other electrolytes or medications.1

Do not freeze. Store diluted solution for no more than 24 hours at 2°C to 8°C (36°F to 46°F) or 4 hours at room temperature (below 25°C [77°F]).1

Administration of Ramucirumab

Administer ramucirumab as an IV infusion only. Do not administer ramucirumab as an IV push or bolus.1

Administer diluted ramucirumab solution via infusion pump through a separate infusion line. Use of a protein sparing 0.22 micron filter is recommended. Flush the line with sterile 0.9% NaCl injection at the end of the infusion.1

If the first 60-minute infusion of ramucirumab is tolerated, then all subsequent infusions may be administered over 30 minutes. This applies to all recommended doses of ramucirumab and all approved indications.1

The infusion set must be flushed post-infusion with sterile 0.9% normal saline equal to or greater than infusion set hold-up volume to ensure delivery of the calculated dose.2

Discard any unused portion of ramucirumab as the product contains no preservatives.1

Enclosed Prescribing Information

CYRAMZA® (ramucirumab) injection, for intravenous use, Lilly

References

1. Cyramza [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Abbreviation

IV = intravenous

Date of Last Review: August 12, 2019


Contact Lilly

Call Us

If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.

Available Mon - Fri, 9am - 7pm EST

Or you can

Chat with us

Chat with us

Submit a Request

Visit Us @LillyMedical